Heat Biologics (HTBX) Files Amended Securities Prospectus Supplement
- Futures inch higher in run-up to corporate earnings
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises on robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
Roth Capital Cuts PT on Heat Biologics (HTBX) by ~27% Following HS-410 Phase 2 Data
December 1, 2016 8:25 AM ESTRoth Capital cuts its price target on Buy-rated Heat Biologics (Nasdaq: HTBX) from $2.75 to $2 following adverse HS-410 combo phase 2 data in bladder cancer, as announced on Wednesday night.
Analyst Joseph Pantginis commented today, Based on the outcome of the Phase II... More
Heat Biologics (HTBX) Shares Hit on Adverse HS-410 Combo Phase 2 Data in Invasive Bladder Cancer
December 1, 2016 8:20 AM ESTHeat Biologics (Nasdaq: HTBX) shares are getting hit early Thursday after the company announced... More